Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-75348780 in relapsed/refractory B-cell NHL and CLL
NCT04540796Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2020
- Primary completion
- Sep 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 1, open-label trial of rezetamig in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Adverse Events, Adverse Events by Severity and 1 more. Started Nov 2020; status: completed.
02
Drugs
rezetamig
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04540796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04540796.